Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

zoetis netherlands holdings b.v. podružnica zagreb za promidžbu, petra hektorovića 2, zagreb, hrvatska - inaktivirani virus leukemije mačaka (felv), podtipovi a, b i c (kawakami-theilen soj), koji uključuje subjedinični antigen (gp70) za poticanje tvorbe anti-gp70 protutijela - suspenzija za injekciju - mačaka (u dobi od 9 tjedana i više)

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

amicus pharma d.o.o. - influenca, inaktivisana, fragmentisani virus ili površinski antigen - suspenzija za injekciju u napunjenoj šprici - 15 µg/0.5 ml+ 15 µg/0.5 ml+ 15 µg/0.5 ml+ 15 µg/0.5 ml - 0,5 ml (1 doza) suspenzije za injekciju u napunjenom špricu sadrži: 15 mcg ha** a/california/7/2009 (h1n1)pdm09sličan soj (a/california/7/2009,nymc x179a) 15 mcg ha 15 mcg ha** a/texas/50/2012 (h3n2)sličan soj (a/texas/50/2012,nymc x223a) 15 mcg ha** b/massachusetts/2/2012 (yamagata lineage) 15 mcg ha** b/brisbane/60/2008 (victoria lineage) *proizveden u oplođenim jajima kokoški iz zdravih jata ** hemaglutinin

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

amicus pharma d.o.o. - influenca, inaktivisana, fragmentisani virus ili površinski antigen - suspenzija za injekciju u napunjenoj šprici - 15 µg/0.5 ml+ 0,5 µg/0.5 ml+ 15 µg/0.5 ml+ 15 µg/0.5 ml - 0,5 ml (1 doza) suspenzije za injekciju u napunjenom špricu sadrži: 15 mcg ha** a/california/7/2009 (h1n1)pdm09sličan soj (a/california/7/2009,nymc x179a) 15 mcg ha 15 mcg ha** a/texas/50/2012 (h3n2)sličan soj (a/texas/50/2012,nymc x223a) 15 mcg ha** b/massachusetts/2/2012 (yamagata lineage) 15 mcg ha** b/brisbane/60/2008 (victoria lineage) *proizveden u oplođenim jajima kokoški iz zdravih jata ** hemaglutinin

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

viatris bh d.o.o. - influenca, inaktivisana, fragmentisani virus ili površinski antigen - suspenzija za injekciju u napunjenoj šprici - 15 µg/0.5 ml+ 15 µg/0.5 ml+ 15 µg/0.5 ml+ 15 µg/0.5 ml - 0,5 ml suspenzije za injekciju sadrži: a/brisbane/02/2018 (h1n1)pdm09– sličan soj (a/brisbane/02/2018, ivr190) 15 mikrograma ha** a/kansas/14/2017 (h3n2) – sličan soj (a/kansas/14/2017, nymc x327) 15 mikrograma ha** b/colorado/06/2017 – sličan soj (b/victoria/2/87 soj) (b/maryland/15/2016, nymc bx69a) 15 mikrograma ha** b/phuket/3073/2013 – sličan soj (b/yamagata/16/88 soj) (b/phuket/3073/2013, divlji tip) 15 mikrograma ha**

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

viatris bh d.o.o. - influenca, inaktivisana, fragmentisani virus ili površinski antigen - suspenzija za injekciju u napunjenoj šprici - 15 µg/0.5 ml+ 15 µg/0.5 ml+ 15 µg/0.5 ml+ 15 µg/0.5 ml - 0,5 ml suspenzijeza injekciju sadrži: a/brisbane/02/2018 (h1n1)pdm09– sličan soj (a/brisbane/02/2018, ivr190) 15 mikrograma ha** a/kansas/14/2017 (h3n2) – sličan soj (a/kansas/14/2017, nymc x327) 15 mikrograma ha** b/colorado/06/2017 – sličan soj (b/victoria/2/87 soj) (b/maryland/15/2016, nymc bx69a) 15 mikrograma ha** b/phuket/3073/2013 – sličan soj (b/yamagata/16/88 soj) (b/phuket/3073/2013, divlji tip) 15 mikrograma ha**

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - radionuklidno slikanje - dijagnostički radiofarmaceutici - ovaj je lijek samo za dijagnostičku uporabu. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - tumori prostate, Кастраци-uporan - terapeutski radiofarmaceutski pripravci - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

curium pet france - piflufolastat (18f) - prostatske neoplazme - dijagnostički radiofarmaceutici - ovaj je lijek samo za dijagnostičku uporabu. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

glaxosmithkline biologicals s.a., rue de l'institut 89, rixensart, belgija - toksoid difterije toksoid tetanusa toksoid hripavca filamentozni hemaglutinin hripavca pertaktin hripavca poliovirus tip 1, soj mahoney (inaktiviran) poliovirus tip 2, soj mef-1 (inaktiviran) poliovirus tip 3, soj saukett (inaktiviran) polisaharid hemofilusa influence tip b (poliribozilribitolfosfat) - prašak i suspenzija za suspenziju za injekciju - 1 doza = 0,5 ml - urbroj: jedna doza (0,5 ml) sadrži najmanje 30 iu toksoida difterije, najmanje 40 iu toksoida tetanusa, 25 µg toksoida hripavca, 25 µg filamentoznog hemaglutinina i 8 µg pertaktina adsorbirane na hidratizirani aluminijev hidroksid (0,5 mg al3+); inaktivirane polioviruse tip 1 (soj mahoney, 40 d-antigen jedinica), 2 (soj mef-1, 8 d-antigen jedinica) i 3 (soj saukett, 32 d-antigen jedinica); 10 µg polisaharida hemofilusa tip b (poliribozilribitolfosfat) konjugiranog na približno 30 µg toksoida tetanusa

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - drugi antineoplastični agensi - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.